Exagen (XGN) Equity Average (2018 - 2026)

Exagen has reported Equity Average for 9 years, with the latest figure at $15.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 99.97% year-over-year to $15.9 million; the trailing twelve-month figure through Mar 2026 stood at $15.9 million (up 99.97% YoY), and the FY2025 full-year result was $13.5 million, down 16.27% from the prior year.
• Equity Average for Q1 2026 stood at $15.9 million, down from $17.8 million in the prior quarter.
• The five-year high for Equity Average was $80.5 million in Q1 2022, with the low at $8.0 million in Q1 2025.
• Historically, Equity Average has averaged $31.1 million across 5 years, with a median of $21.3 million in 2024.
• Annual changes were most pronounced in 2025 — Equity Average slumped 62.65% — and 2026, when it soared 99.97%.
• Exagen's Equity Average stood at $49.3 million in 2022, then tumbled by 49.11% to $25.1 million in 2023, then plunged by 55.36% to $11.2 million in 2024, then soared by 58.81% to $17.8 million in 2025, then slipped by 10.41% to $15.9 million in 2026.
• The last three Equity Average figures came in at $15.9 million (Q1 2026), $17.8 million (Q4 2025), and $19.6 million (Q3 2025), per Business Quant data.